Ascendis Pharma: Rare Disease Player Is A Buy On Yorvipath Launch Trajectory

Arcutis Biotherapeutics: Topical Derm Player Continues To Execute

Humacyte: Expect A Slow Launch, But Vascular Trauma Indication Is Just A Beginning

Finding Winners In Biotech, Probably The Riskiest Sector

Sutro Biopharma: Post ESMO Selloff, Does Their Strategy In FRα Remain Viable?

Voyager Therapeutics: CNS Player In Early Stages Of A Turnaround

Biotech's Hidden Gems: Smart Strategies For A Challenging Market

Black Diamond Therapeutics: MasterKey Approach Validated With Lung Cancer Update

Seeking Schadenfreude - Part 2: Lessons Learned

Seeking Schadenfreude - Part 1: The One That Got Away

Amylyx Pharmaceuticals: Post Q1 Selloff Appears Overdone

Fulcrum Therapeutics: FSHD Steadily Advancing In Phase 3, Optionality With SCD

Orchard Therapeutics: MLD Opportunity Could Be Larger Than Initial Estimates

Xeris Biopharma: Picks And Shovels Play Has Long-Term Growth Potential

Karyopharm Therapeutics: Expanding Beyond The Crowded Multiple Myeloma Market

Inozyme Pharma: Rare Disease Player Merits Revaluation Higher After POC Data

Rain Oncology: Multiple Data Catalysts In 2023 For This Precision Oncology Pioneer

AVITA Medical: Experienced CEO Taking The Helm As Expansion Opportunities Await

Marketplace Roundtable - 2023 Look Ahead - Biotech And Healthcare Coverage

Fate Therapeutics: iPSC Pioneer A Buy For Long-Term Investors

Deciphera Pharmaceuticals: Encouraging Sales Growth For Qinlock But Risk/Reward Remains Unattractive

Avidity Biosciences: Proof-Of-Concept Achieved In DM1 For AOC Platform

Eton Pharmaceuticals: Alkindi Sprinkle Leads Growth In Orphan Disease Portfolio

Nkarta: A Buy On Pullback With Valuation At Lows

ImmunoGen Needs To Make The Most Of Its First-Mover Opportunity